108 related articles for article (PubMed ID: 27481174)
1.
Eiber M; Herrmann K; Fendler WP; Maurer T
Eur Urol; 2016 Dec; 70(6):938-940. PubMed ID: 27481174
[No Abstract] [Full Text] [Related]
2. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
3. Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive
Zattoni F; Zattoni F; Evangelista L
Eur Urol; 2017 Feb; 71(2):e64-e65. PubMed ID: 27591933
[No Abstract] [Full Text] [Related]
4. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
5. Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive
Papa N; Perera M; Hofman MS; Bolton D; Lawrentschuk N
Eur Urol; 2017 Feb; 71(2):e66-e67. PubMed ID: 27597236
[No Abstract] [Full Text] [Related]
6. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
Sonni I; Baratto L; Iagaru A
PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
[TBL] [Abstract][Full Text] [Related]
7. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
Schlenkhoff CD; Gaertner F; Essler M; Hauser S; Ahmadzadehfar H
Clin Nucl Med; 2016 May; 41(5):423-5. PubMed ID: 26859213
[TBL] [Abstract][Full Text] [Related]
10. Is
Chandrasekar T; Ost P; Tilki D
Eur Urol; 2018 May; 73(5):662-663. PubMed ID: 29472144
[No Abstract] [Full Text] [Related]
11. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
12. Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Wetter A
Int J Urol; 2014 Dec; 21(12):1288. PubMed ID: 25138830
[No Abstract] [Full Text] [Related]
13.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Maurer T; Beer AJ; Wester HJ; Kübler H; Schwaiger M; Eiber M
Int J Urol; 2014 Dec; 21(12):1286-8. PubMed ID: 25047368
[No Abstract] [Full Text] [Related]
16. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
18. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma.
Militano V; Afaq A; Bomanji J
Clin Nucl Med; 2019 Feb; 44(2):e90-e92. PubMed ID: 30608915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
